SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins.
We have identified secreted protein acidic and rich in cysteine (SPARC) as a potential glioma invasion-promoting gene. To determine whether SPARC alters the growth, attachment, or migration of gliomas, we have used U87T2 and doxycycline-regulatable SPARC-transfected clones to examine the effects of SPARC on (1) cell growth, (2) cell cycle progression, (3) cell attachment, and (4) cell migration, using growth curves, flow cytometry, attachment, and migration analyses on different brain ECMs, including collagen IV, laminin, fibronectin, vitronectin, hyaluronic acid, and tenascin. Our data indicate that SPARC delays tumor cell growth in the log phase of the growth curve. The clones secreted different levels of SPARC. The clone secreting the lowest level of SPARC was associated with a higher percentage of cells in G2M, whereas the clones secreting the higher levels of SPARC were associated with a greater percentage of cells in G0/G1. In comparison to the parental U87T2 clone, the SPARC-transfected clones demonstrated increased attachment to collagen, laminin, hyaluronic acid, and tenascin, but not to vitronectin or fibronectin. SPARC-transfected clones also demonstrated altered migration on the different extracellular matrix proteins. The modulation of migration, either positive or negative, was associated with changes in the level of secreted SPARC. These data suggest that SPARC may modulate glioma proliferation and invasion by modulating both the growth and migration of glioma cells.
Rempel
S A
SA
Department of Neurosurgery, Henry Ford Health Sciences Center, Detroit, MI 48202, USA. nssan@neuro.hfh.edu
Golembieski
W A
WA
Fisher
J L
JL
Maile
M
M
Nakeff
A
A
D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology*; D002448:Cell Adhesion; D002455:Cell Division; D002465:Cell Movement; D003094:Collagen / Q000378:metabolism; D016326:Extracellular Matrix Proteins / Q000378:metabolism*; D005353:Fibronectins / Q000378:metabolism; D016193:G1 Phase; D005910:Glioma / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D006820:Hyaluronic Acid / Q000378:metabolism; D007797:Laminin / Q000378:metabolism; D009363:Neoplasm Proteins / Q000502:physiology*; D015676:Osteonectin / Q000235:genetics / Q000502:physiology*; D011993:Recombinant Fusion Proteins / Q000502:physiology; D016192:Resting Phase, Cell Cycle; D019063:Tenascin / Q000378:metabolism; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000378:metabolism / Q000473:pathology; D019096:Vitronectin / Q000378:metabolism
D016326:Extracellular Matrix Proteins; D005353:Fibronectins; D007797:Laminin; D009363:Neoplasm Proteins; D015676:Osteonectin; D011993:Recombinant Fusion Proteins; D019063:Tenascin; D019096:Vitronectin; D006820:Hyaluronic Acid; D003094:Collagen